TWD 19.65
(-0.51%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 439.51 Million TWD | -8.17% |
2022 | 486.02 Million TWD | 21.25% |
2021 | 400.86 Million TWD | 36.48% |
2020 | 293.71 Million TWD | 0.0% |
2019 | 282.41 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 289.03 Million TWD | 189.97% |
2024 Q2 | 73.56 Million TWD | -74.55% |
2023 Q3 | 99.67 Million TWD | 4.0% |
2023 FY | - TWD | -8.17% |
2023 Q4 | 99.67 Million TWD | 0.0% |
2023 Q2 | 95.84 Million TWD | 0.0% |
2023 Q1 | 95.84 Million TWD | -1.91% |
2022 FY | - TWD | 21.25% |
2022 Q4 | 97.71 Million TWD | 0.0% |
2021 FY | - TWD | 36.48% |
2020 FY | - TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Lytone Enterprise, Inc. | 58.83 Million TWD | -647.033% |
Vetnostrum Animal Health Co., Ltd. | 191.74 Million TWD | -129.223% |